Fig. 2

A, B Through Western blot (WB) analysis in 19 pairs of HCC samples, it was found that STAMBPL1 is primarily significantly overexpressed in HCC. C–E Detection through immunohistochemistry (IHC) in 19 pairs of HCC samples revealed a significantly high expression of STAMBPL1, primarily in HCC. F–I Further analysis using tissue microarray (90 pairs of liver cancer and adjacent tissues) revealed that STAMBPL1 is significantly highly expressed, particularly in HCC. J Further confirmation through tissue microarray analysis (90 pairs of HCC and adjacent tissues) validated a significant positive correlation between the expression level of STAMBPL1 and the pathological grade of HCC. K Using the GEPIA online database, it was found that the overall survival (OS) is shorter in the high STAMBPL1 expression group compared to the low STAMBPL1 expression group. L Using the GEPIA online database, it was found that the disease-free survival (DFS) is shorter in the high STAMBPL1 expression group compared to the low STAMBPL1 expression group. M By combining tissue microarray data with the corresponding patient survival data, it was observed that the high STAMBPL1 expression exhibits a reduced overall survival duration when contrasted with the low expression group. N The Immunofluorescence staining assay shows that STAMBPL1, along with the common tumor antigens Ki-67 and PCNA, are highly expressed in tumor tissues. O–P The Immunofluorescence assay showed that STAMBPL1, E-Cadherin, Vimentin, and N-Cadherin were all highly expressed in tumor tissues, and their expression trends were positively correlated